By James Jardine
Cell and gene therapy (CGT) has grown from being considered a niche sector of biopharma, into the most rapidly expanding and investor-enticing product pipeline in the life sciences. With 1,300 companies actively involved in CGT manufacturing and 11 gene therapy medicinal products with valid marketing authorization, the question now becomes how to bring those innovative therapies to market.
Here we learn the importance of possessing a streamlined processes, flexible systems, and the scalability and manufacturing capacity to adequately support production, clinical trials, and approval processes. We also explore the importance of new cell and gene therapy software solutions and the role of the cell and gene therapy CMO.